<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228029</url>
  </required_header>
  <id_info>
    <org_study_id>KasrEliniH</org_study_id>
    <nct_id>NCT04228029</nct_id>
  </id_info>
  <brief_title>Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids</brief_title>
  <official_title>Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with three lesions of alopecia areata are randomly recruited in this study. Each
      lesion is randomized in to receiving either carboxytherapy in one lesion, intralesional
      steroids in another lesion and combination of both in the third lesion.

      Treatment period is 3 months followed by a follow-up period of 2 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">April 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Alopecia Tool (SALT) score</measure>
    <time_frame>6months-1 year</time_frame>
    <description>evaluate efficacy of carboxytherapy versus intralesional steroids versus combination of both Minimum value is 0% and maximum value is100% the higher the score the more the hair loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dermoscopy</measure>
    <time_frame>6months-1 year</time_frame>
    <description>evaluate efficacy of carboxytherapy versus intralesional steroids versus combination of both through counting number dystrophic hair, tapered hair, regrowing hair, black dots, and yellow dots</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blinded observer evaluation by use of photography</measure>
    <time_frame>6months-1 year</time_frame>
    <description>evaluate efficacy of carboxytherapy versus intralesional steroids versus combination of both</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient satisfaction rate</measure>
    <time_frame>6months-1 year</time_frame>
    <description>evaluate efficacy of carboxytherapy versus intralesional steroids versus combination of both</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Carboxytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of carboxytherapy and intralesional steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carboxytherapy</intervention_name>
    <description>Carbon dioxide (CO2) gas in injection form</description>
    <arm_group_label>Carboxytherapy</arm_group_label>
    <arm_group_label>Combination of carboxytherapy and intralesional steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralesional Steroid Injection</intervention_name>
    <description>triamcinolone acetonide 8 mg/mL</description>
    <arm_group_label>Combination of carboxytherapy and intralesional steroids</arm_group_label>
    <arm_group_label>Intralesional steroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  early localized scalp alopecia areata

          -  patients who did not receive any medication for at least 2 months before starting the
             study Patients who agreed to join the study and signed written consent.

        Exclusion Criteria:

          -  pregnant, and lactating females and those with unrealistic expectation.

          -  Alopecia totalis or universalis or ophiasis or cicatrising alopecia

          -  Usage of systemic treatment of alopecia areata 2 months prior to the study.

          -  Any scalp lesion within the treated area

          -  Bleeding diathesis, severe anemia or platelet disorders

          -  Medical conditions such as autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kasr ElAiny Hospital, Cairo university</name>
      <address>
        <city>Cairo</city>
        <state>El Manial</state>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Rana F Hilal, MD</investigator_full_name>
    <investigator_title>Lecturer of dermatology, faculty of Medicine, Cairo University.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

